[go: up one dir, main page]

WO2000066094A3 - Verwendung von verbindungen mit einem stickstoff-sauerstoff-heterocyclus als antiinfektiöse mittel - Google Patents

Verwendung von verbindungen mit einem stickstoff-sauerstoff-heterocyclus als antiinfektiöse mittel Download PDF

Info

Publication number
WO2000066094A3
WO2000066094A3 PCT/EP2000/003959 EP0003959W WO0066094A3 WO 2000066094 A3 WO2000066094 A3 WO 2000066094A3 EP 0003959 W EP0003959 W EP 0003959W WO 0066094 A3 WO0066094 A3 WO 0066094A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
atom
group
nitrogen
infectious agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/003959
Other languages
English (en)
French (fr)
Other versions
WO2000066094A2 (de
Inventor
Hassan Jomaa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jomaa Pharmaka GmbH
Original Assignee
Jomaa Pharmaka GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jomaa Pharmaka GmbH filed Critical Jomaa Pharmaka GmbH
Priority to US09/980,611 priority Critical patent/US6638957B1/en
Priority to AU50639/00A priority patent/AU771339B2/en
Priority to EP00934979A priority patent/EP1173183A2/de
Priority to CA002369526A priority patent/CA2369526A1/en
Priority to JP2000614979A priority patent/JP2002543113A/ja
Publication of WO2000066094A2 publication Critical patent/WO2000066094A2/de
Publication of WO2000066094A3 publication Critical patent/WO2000066094A3/de
Priority to NO20015368A priority patent/NO20015368L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Die Erfindung betrifft die Verwendung von Verbindungen der allgemeinen Formel (I), wobei Y eine C1-3-Alkenylengruppe ist, wobei B aus der Gruppe ausgewählt ist, die aus C1-26-Alkenylengruppen besteht, wobei ein C-Atom durch ein Sauerstoffatom und ein C-Atom durch ein Schwefelatom ersetzt sein können oder zwei C-Atome durch einen S-Heterocyclus ersetzt sein können, und wobei X für die phosphororganische Gruppe (a) oder für die Aminogruppe (b) steht, zur Inhibition des 1-Desoxy-D-xylulose-5-phosphat-(DOXP)-Stoffwechselweges, ihre Verwendung als Herbizid und zur Herstellung eines Arzneimittels sowie ein Verfahren zur therapeutischen und prophylaktischen Behandlung von Infektionen bei Mensch und Tier, verursacht durch Viren, Bakterien, Pilze und Parasiten.
PCT/EP2000/003959 1999-05-03 2000-05-03 Verwendung von verbindungen mit einem stickstoff-sauerstoff-heterocyclus als antiinfektiöse mittel Ceased WO2000066094A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/980,611 US6638957B1 (en) 1999-05-03 2000-05-03 Use of compounds with a nitrogen-oxygen heterocycle
AU50639/00A AU771339B2 (en) 1999-05-03 2000-05-03 Use of compounds with a nitrogen-oxygen heterocycle
EP00934979A EP1173183A2 (de) 1999-05-03 2000-05-03 Verwendung von verbindungen mit einem stickstoff-sauerstoff-heterocyclus als antiinfektiöse mittel
CA002369526A CA2369526A1 (en) 1999-05-03 2000-05-03 Use of compounds with a nitrogen-oxygen heterocycle as anti-infectious agents
JP2000614979A JP2002543113A (ja) 1999-05-03 2000-05-03 窒素−酸素複素環を含む化合物の使用
NO20015368A NO20015368L (no) 1999-05-03 2001-11-02 Anvendelse av forbindelser omfattende en nitrogen-oksygen- heteroring

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19920247A DE19920247A1 (de) 1999-05-03 1999-05-03 Arzneimittel mit einem Gehalt an Verbindungen mit einem Stickstoff-Sauerstoff-Heterocyclus als Wirkstoff und ihre Verwendung
DE19920247.8 1999-05-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/980,611 A-371-Of-International US6638957B1 (en) 1999-05-03 2000-05-03 Use of compounds with a nitrogen-oxygen heterocycle
US10/434,164 Continuation US20040033994A1 (en) 1999-05-03 2003-05-09 Use of compounds comprising a nitrogen-oxygen heterocycle

Publications (2)

Publication Number Publication Date
WO2000066094A2 WO2000066094A2 (de) 2000-11-09
WO2000066094A3 true WO2000066094A3 (de) 2001-08-09

Family

ID=7906777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003959 Ceased WO2000066094A2 (de) 1999-05-03 2000-05-03 Verwendung von verbindungen mit einem stickstoff-sauerstoff-heterocyclus als antiinfektiöse mittel

Country Status (8)

Country Link
US (2) US6638957B1 (de)
EP (1) EP1173183A2 (de)
JP (1) JP2002543113A (de)
AU (1) AU771339B2 (de)
CA (1) CA2369526A1 (de)
DE (1) DE19920247A1 (de)
NO (1) NO20015368L (de)
WO (1) WO2000066094A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078714A1 (de) * 2001-03-30 2002-10-10 Jomaa Pharmaka Gmbh Magensaftresistente formulierungen zur applikation von antiinfektiös wirkenden verbindungen, die den 2-c-methylerythrose-4-stoffwechselweg hemmen, sowie ihren salzen und estern
DE10201458A1 (de) * 2001-04-11 2002-10-17 Adelbert Bacher Intermediate und Enzyme des Mevalonat-unabhängigen Isoprenoidbiosyntheseweg
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US8329924B2 (en) 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
US20050124586A1 (en) * 2002-02-11 2005-06-09 Phan Hieu T. Alpha-substituted arylalkyl phosphonate derivatives
US7402608B2 (en) 2002-12-10 2008-07-22 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
DE10356410A1 (de) * 2003-11-24 2005-06-23 Bioagency Ag Phosphororganische Verbindungen und deren Verwendung
SG161315A1 (en) 2005-05-13 2010-05-27 Virochem Pharma Inc Compounds and methods for the treatment or prevention of flavivirus infections
US9037466B2 (en) * 2006-03-09 2015-05-19 Nuance Communications, Inc. Email administration for rendering email on a digital audio player
BRPI0718915A2 (pt) 2006-11-15 2013-12-03 Virochem Pharma Inc Análogos de tiofeno para o tratamento ou prevenção de infecções por flavivírus
WO2013055674A1 (en) * 2011-10-10 2013-04-18 The University Of Toledo Method for treating infections
CN103936790B (zh) * 2014-04-17 2015-11-18 中国农业科学院植物保护研究所 异恶唑衍生物、制备方法以及杀虫组合物
CN114158508B (zh) * 2021-11-30 2023-07-25 海南归耘田农业科技有限公司 一种有效预防小龙虾受寄生虫感染的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3418317A (en) * 1965-10-12 1968-12-24 Lepetit Spa 1h-2,3-benzoxazine-4(3h)-one and its 3- and/or 6-substituted derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6026119B2 (ja) * 1977-06-09 1985-06-21 三共株式会社 有機リン酸エステル類およびそれを含有する殺虫殺ダニ剤
US4405357A (en) 1980-06-02 1983-09-20 Fmc Corporation Herbicidal 3-isoxazolidinones and hydroxamic acids
US4897489A (en) * 1984-12-18 1990-01-30 Takeda Chemical Industries, Ltd. Antibiotic derivatives, their production and use
JPS63119476A (ja) * 1986-11-05 1988-05-24 Takeda Chem Ind Ltd イソキサゾリドン誘導体
JPH07291992A (ja) * 1994-04-27 1995-11-07 Sankyo Co Ltd 新規化合物ｂ４３１７

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3418317A (en) * 1965-10-12 1968-12-24 Lepetit Spa 1h-2,3-benzoxazine-4(3h)-one and its 3- and/or 6-substituted derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMSTUTZ, RENE ET AL: "Position 5 at the oxotremorine skeleton as the steering position for activity at the muscarinic receptors", HELV. CHIM. ACTA (1987), 70(8), 2232-44, XP000981927 *
HALL, IRIS H. ET AL: "Synthesis and cytotoxic action of 3,5-isoxazolidinediones and 2-isoxazolin-5-ones in murine and human tumors", ARCH. PHARM. (WEINHEIM, GER.) (1997), 330(3), 67-73, XP000983056 *
LIU SONG YU ET AL: "Microbial transformations of clomazone.", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 44, no. 1, 1996, pages 313 - 319, XP000981932, ISSN: 0021-8561 *
SLAWIK, TOMASZ ET AL: "Synthesis of 3-(3-oxo-1,2-benzisoxazol-2-yl)propionic acids derivatives", ACTA POL. PHARM. (1997), 54(5), 375-379, XP000986556 *

Also Published As

Publication number Publication date
AU771339B2 (en) 2004-03-18
DE19920247A1 (de) 2000-11-16
US20040033994A1 (en) 2004-02-19
JP2002543113A (ja) 2002-12-17
CA2369526A1 (en) 2000-11-09
WO2000066094A2 (de) 2000-11-09
NO20015368D0 (no) 2001-11-02
AU5063900A (en) 2000-11-17
EP1173183A2 (de) 2002-01-23
US6638957B1 (en) 2003-10-28
NO20015368L (no) 2001-11-02

Similar Documents

Publication Publication Date Title
CY1108367T1 (el) Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου
WO2000066094A3 (de) Verwendung von verbindungen mit einem stickstoff-sauerstoff-heterocyclus als antiinfektiöse mittel
BRPI0411016A (pt) composições antisépticas, processos e sistemas
WO1999052515A3 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
MXPA04002648A (es) Tratamiento artropodicida con antranilamida.
WO2010115184A3 (en) Hydroxythienoquinolones and related compounds as anti-infective agents
CY1109245T1 (el) Ενωσεις χρησιμες στην θεραπεια ανθρακα και στην αναστολη θανατηφορου παραγοντα
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
BR0215032A (pt) Composição herbicidamente ativa, método para controlar vegetação indesejável, e, uso de composições
YU2201A (sh) Fosfororganska jedinjenja i njihova upotreba
MXPA02006051A (es) Compuestos de amonio cuaternario ciclico.
WO2000044359A3 (de) Verwendung von thiadiazolderivaten zur prophylaktischen und therapeutischen behandlung von infektionen
TR200101841T2 (tr) Enfeksiyonlardan korunmak ve enfeksiyon tedavisi için bifosfonatların kullanılmaları
AP2001002165A0 (en) Use of phosphonoformic acid derivatives for treating infections
NO20011430L (no) Anvendelse av organofosforforbindelser for fremstilling av medikamenter for terapeutisk og profylaktisk behandling avinfeksjoner, eller som et fungicid, baktericid eller herbicid forplanter
BR9815339A (pt) Composição fungicida e/ou bactericida, processo de controle dos fungos fitopatogênicos ou bactérias de um meio, processo de combate, a tìtulo curativo ou preventivo, dos fungos fitopatogênicos das culturas e/ou das bactérias e produto
WO2000044358A3 (de) Verwendung von phosphororganischen verbindungen zur prophylaktischen und therapeutischen behandlung von infektionen
PT1175429E (pt) Derivados halo de 9-desoxo-9a-aza-9a-homoeritromicina a
NO20061355L (no) Fungicide blandinger for kontroll av rispatogener
WO2000030653A3 (de) Verwendung von phosphonoameisensäurederivaten zur behandlung von infektionen
EP1500656A4 (de) Biguanidderivat und therapeutisches diabetesmittel, das dieses enthält
WO2002018354A8 (en) Oxazolidinones and their use as antibacterial agents
MXPA05013760A (es) Composicion y procedimiento de tratamiento del platanero y del bananero.
HRP20070055T3 (hr) Fungicidne smjese na bazi derivata triazolopirimidina

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 50639/00

Country of ref document: AU

Ref document number: IN/PCT/2001/01281/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2369526

Country of ref document: CA

Ref document number: 2369526

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 09980611

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2000 614979

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000934979

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000934979

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 50639/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000934979

Country of ref document: EP